NOXXON Pharma
  • About
    • Management
    • Supervisory Board
    • Scientific Advisory Board
  • Pipeline
    • Pipeline
    • NOX-A12
    • NOX-E36
    • Collaborations
  • Scientific Approach
    • Tumor Microenvironment
    • Technology
    • Scientific Publications
  • Investors
    • CEO Message
    • NOXXON in brief
    • Press Releases
    • Documentation
    • Corporate Governance
    • NOXXON and the Market
  • Media
  • Contact
    • Careers
  • french
  • linkedin
  • twitter

About NOXXON

NOXXON’s oncology-focused pipeline breaks the tumor protection barrier and blocks tumor repair by neutralizing chemokines in the tumor micro-environment (TME). NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact.

After NOXXON’s lead program NOX-A12 delivered final top-line data with encouraging overall survival and safety profile from a combination trial with an anti-PD-1 immuno-oncology checkpoint inhibitor in metastatic colorectal and pancreatic cancer patients in September 2020, the company announced in July 2021 its upcoming Phase 2 study to further evaluate safety and efficacy of NOX-A12 in combination with anti-PD-1 and two different chemotherapy regimens as second-line therapy in patients with  pancreatic cancer.

The combination of NOX-A12 and radiotherapy has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. An ongoing trial of NOX-A12 in combination with radiotherapy in newly diagnosed brain cancer patients who will not benefit from standard chemotherapy has delivered interim data from the low- and mid-dose cohorts showing consistent tumor reductions. The read-out from the third high-dose cohort is expected in early 2022.

The company’s second clinical-stage asset, NOX-E36 is a TME asset targeting the innate immune system and is planned to go back into the clinic in 2021. NOXXON plans to develop NOX-E36 in patients with solid tumors.

KOL Webinar with Dr. Frank Giordano on NOX-A12 & Radiotherapy Combination in Brain Cancer incl. Data Presented at the SNO Annual Meeting (November 2021)
To view the recording click HERE

• Read the CEO Letter to our shareholders

Press Release

Berlin, Germany

2022, May 11
08:00 a.m.

NOXXON appoints leading brain cancer experts to scientific advisory board

2022, April 22
06:00 p.m.

NOXXON reports 2021 financial results

2022, April 21
06:00 p.m.

NOXXON announces €2.375 million financing under agreement with Atlas


Events

TIDES USA Oligonucleotide and Peptide Therapeutics

Aram Mangasarian
May 8 – 12, Boston

Bio Equity Europe

Aram Mangasarian
May 17-18, Milan

ASCO Annual Meeting

Aram Mangasarian, Avital Barak
June 3 – 8, Chicago

BIO International Convention

Aram Mangasarian
June 13 – 16, San Diego

2nd Tumor Myeloid-Directed Therapies Summit

Anna Frömming
June 14–16, Boston


* Spiegelmer® is a registered trademark of NOXXON Pharma

Imprint | Disclaimer | Privacy Policy |


© NOXXON Pharma 2022

Usage of Cookies

We use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about our use of cookies can be found in our privacy policy. If you continue to use this website we will assume that you agree with the usage of cookies. You can prevent cookies from being installed or delete them from your computer. How this works, is explained in our privacy policy.

You have declined cookies. This decision can be reversed.

You have allowed cookies to be placed on your computer.

Usage of Cookies

We use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about our use of cookies can be found in our privacy policy. If you continue to use this website we will assume that you agree with the usage of cookies. You can prevent cookies from being installed or delete them from your computer. How this works, is explained in our privacy policy.